XENE logo

XENE
Xenon Pharmaceuticals Inc

2,742
Mkt Cap
$5.27B
Volume
693,981.00
52W High
$63.95
52W Low
$28.19
PE Ratio
-12.44
XENE Fundamentals
Price
$54.26
Prev Close
$55.24
Open
$55.03
50D MA
$52.70
Beta
0.84
Avg. Volume
2.28M
EPS (Annual)
-$4.36
P/B
7.46
Rev/Employee
$20,270.27
$3,011.21
Loading...
Loading...
News
all
press releases
Xenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton Conference
Xenon Pharmaceuticals (NASDAQ:XENE) provided an update on its clinical and pipeline progress at the Bloom Burton conference, with CEO Ian Mortimer highlighting recent Phase III results for lead program azetukalner, plans for regulatory filings, and continued expansion into psychiatry and pain. Lead...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Peregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENE
Peregrine Capital Management LLC acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the fourth quarter, according to the company in its most recent...
MarketBeat·4d ago
News Placeholder
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by Brokerages
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has received a consensus recommendation of "Buy" from the nineteen analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a buy rating...
MarketBeat·17d ago
News Placeholder
Xenon Pharmaceuticals (NASDAQ:XENE) Sees Strong Trading Volume - What's Next?
Xenon Pharmaceuticals (NASDAQ:XENE) Sees Large Volume Increase - Should You Buy...
MarketBeat·22d ago
News Placeholder
Aberdeen Group plc Increases Stock Position in Xenon Pharmaceuticals Inc. $XENE
Aberdeen Group plc raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 29.6% in the 4th quarter, according to its most recent 13F filing with the Securities...
MarketBeat·23d ago
News Placeholder
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This represents an...
MarketBeat·26d ago
News Placeholder
Assenagon Asset Management S.A. Invests $5.34 Million in Xenon Pharmaceuticals Inc. $XENE
Assenagon Asset Management S.A. acquired a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F...
MarketBeat·1mo ago
News Placeholder
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?
Xenon Pharmaceuticals (NASDAQ:XENE) Share Price Crosses Above 50-Day Moving Average - Should You Sell...
MarketBeat·1mo ago
News Placeholder
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know
Key PointsThe chief medical officer of Xenon Pharmaceuticals directly sold 1,410 common shares for a transaction value of $78,000 on March 13, 2026...
Nasdaq News: Markets·1mo ago
News Placeholder
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
Zacks·1mo ago
<
1
2
...
>

Latest XENE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.